Stocks & Investing
Stocks and Investing
Stocks and Investing
Fri, May 3, 2024
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
Matt O"Brien Reiterated (TNDM) at Buy with Increased Target to $50 on, May 3rd, 2024
Matt O"Brien of Piper Sandler, Reiterated "Tandem Diabetes Care, Inc." (TNDM) at Buy with Increased Target from $35 to $50 on, May 3rd, 2024.
Matt has made no other calls on TNDM in the last 4 months.
There are 3 other peers that have a rating on TNDM. Out of the 3 peers that are also analyzing TNDM, 2 agree with Matt"s Rating of Hold. Following are those relevant analyst calls for the last 4 months;
Joanne Wuensch of "Citigroup" Maintained at Hold with Increased Target to $38 on, Wednesday, April 3rd, 2024 Rick Wise of "Stifel" Maintained at Hold with Increased Target to $24 on, Monday, February 5th, 2024
This is the rating of the analyst that currently disagrees with Matt;
Mike Kratky of "Leerink Partners" Upgraded from Hold to Buy and Increased Target to $45 on, Thursday, April 25th, 2024
